Kuvan (sapropterin dihydrochloride)
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)
June 2016
ADVERSE REACTIONS
Clincial Trials Experiences
PKU Clinical Studies
In Study 7, 27 pediatric patients with PKU aged...
Source: Drugs.com - Labeling Changes - Category: Drugs & Pharmacology Source Type: alerts